相关实验视频

Updated: Feb 28, 2026

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

m5C:针对非酒精性脂肪肝炎的新型诊断和药物重定向目标

Shuxian Chen¹, Renquan Duan², Jingyi Qiu¹

¹Department of Gastroenterology, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang, China, hbmu.edu.cn.

International journal of genomics

|February 27, 2026

概括

RNA5-甲基细胞蛋白 (m5C) 在非酒精性脂肪肝炎 (NASH) 中起作用. 这项研究确定了与m5C相关的枢纽基因,ERCC2和FOXC2,以及一种潜在的治疗药物,BRD-K93672499,用于NASH精准医学.

科学领域:

生物化学生物化学
基因组学就是基因组学.
免疫学免疫学免疫学

背景情况:

RNA5-甲基细胞蛋白 (m5C) 是肝脏新陈代谢和免疫反应中的关键表观遗传调节剂.
在非酒精性脂肪肝炎 (NASH) 发病过程中m5C的具体机制尚不清楚.

研究的目的:

为了阐明m5C在NASH病变发生中的作用.
在NASH中识别m5C相关的分子子组和枢纽基因.
探索潜在的治疗策略,以针对m5C通路为NASH治疗目标.

主要方法:

利用NASH患者的大量RNA测序数据和综合生物信息分析,包括LIMA,共识聚类和机器学习.
分析了单细胞转录基因数据,以破译m5C相关枢纽基因的异质性.
采用人工智能驱动的药物丰富 (DrugReflector) 和分子对接来识别治疗剂.
进行了体外研究,以验证基因表达水平.

主要成果:

根据m5C模式确定了NASH患者的两个不同的分子和免疫子组.
在NASH中发现ERCC2和FOXC2作为上调的m5C相关的枢纽基因,主要位于胆血管细胞中.
确定BRD-K93672499作为NASH中ERCC2和FOXC2的潜在多目标治疗剂.

结论:

这项研究强调了m5C在NASH中的预测和治疗潜力.
研究结果为NASH患者提供了个性化和精准医学方法的见解.
ERCC2和FOXC2是NASH干预的关键目标.

关键词:

药物重用是为了改变药物的用途.m5C 在线观看机器学习是机器学习.多种多种多种多种多种多种多种多种多种多种.没有酒精含量的型肝炎.

更多相关视频

Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery

Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery

Published on: May 19, 2018

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

相关概念视频

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...

Ultrasound II: Endoscopic Ultrasound and FibroScan

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):

Targets for Drug Action: Overview

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...